Compare

Bioxytran, Inc vs Provectus Biopharmaceuticals, Inc. vs Ocean Biomedical, Inc. vs NeuroSense Therapeutics Ltd.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearBioxytran, Inc
BIXT
Provectus Biopharmaceuticals, Inc.
PVCT
Ocean Biomedical, Inc.
OCEALast annual report: year ended 2024-12-31
NeuroSense Therapeutics Ltd.
NRSN
Year ended2025-12-312025-12-312024-12-312025-12-31
Revenuen/a$336.1Kn/an/a
Revenue growth (YoY)n/a-45.5%n/an/a
Gross marginn/an/an/an/a
Operating marginn/an/mn/an/a
Net marginn/an/mn/an/a
Net income-$2.12M-$5.43M-$9.48M-$11.12M
EPS (Diluted)-$0.02-$0.01-$0.34-$0.44
Operating cash flow-$526.5K-$3.33M-$4.18M-$7.67M
Free cash flown/an/an/a-$7.68M
Cash & equivalentsn/a$251.3Kn/a$166.0K
Total assets$658.6K$697.5K$902.0K$1.03M
Total liabilities$3.25M$7.00M$98.52M$2.59M
Shareholders' equity-$2.59M-$6.30M-$97.62M-$1.56M
Return on year-end equityn/an/an/an/a
Shares outstanding108.15M420.28M34.87M32.56M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearBioxytran, IncProvectus Biopharmaceuticals, Inc.Ocean Biomedical, Inc.NeuroSense Therapeutics Ltd.
Latest$191.1K
Ended 2017-12-31
$336.1K
Ended 2025-12-31
n/an/a
1 year earlier$246.5K
Ended 2016-12-31
$617.1K
Ended 2024-12-31
n/an/a
2 years earlier$255.8K
Ended 2015-12-31
$557.7K
Ended 2023-12-31
n/an/a
3 years earlier$275.6K
Ended 2014-12-31
$989.0K
Ended 2022-12-31
n/an/a
4 years earlier$417.3K
Ended 2013-12-31
n/an/an/a